Patient Resources

Support for Patients

Our Patient Programs

Fertility Out Loud is a comprehensive program where patients can explore, self-educate, and reinforce what they learned at the clinic. It further supports patients by providing help with:

  • understanding fertility challenges and treatment options
  • navigating insurance coverage
  • finding a reproductive endocrinologist in their area
  • preparing for their appointments
  • connecting to a community

Guidance along the patient journey

Fertility Out Loud works with advocates and aspiring parents who are on a variety of paths to parenthood. The information provided can support what patients learn from their provider.

Visit Fertility Out Loud

Fertility Outreach offers personalized guidance from trained fertility coaches in English or Spanish, at no cost,*† and can provide patients with:

  • access to credible information and resources
  • support through trusted experience
  • education on fertility topics pertaining to a patient’s personal journey

Real-time support

Patients are sending an average of 5 text messages to our coaches when they have questions—complementing the care they receive at the clinic.

*The information Fertility Outreach fertility coaches provide is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Standard data and message rates may apply.

†Fertility coaches respond to all messages Monday through Friday, 8 AM-8 PM ET.

Visit Fertility OutReach

MyBirthPlan can prepare parents for their birth experience by helping them:

  • personalize their plan
  • plan for the unexpected
  • discover pregnancy topics and tips
  • get answers to questions
Visit MyBirthPlan

Fertility 101

This is a great resource for new or prospective patients, offering comprehensive information on fertility testing and the IVF process.

Download Brochure

Treatment Support

Ferring provides videos and resources that can walk patients through the process and help them prepare.

Administering MENOPUR

Injection Training Video

Download Injection Guide

MENOPUR® (menotropins for injection)

INDICATION FOR USE

  • MENOPUR® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an Assisted Reproductive Technology (ART) program. 

IMPORTANT SAFETY INFORMATION

  • MENOPUR is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman
  • MENOPUR should only be used by physicians who are thoroughly familiar with infertility problems. MENOPUR is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with MENOPUR. There have been infrequent reports of ovarian neoplasms with MENOPUR. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with MENOPUR.
  • The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

Administering NOVAREL

Injection Training Video

Download Injection Guide

NOVAREL® (chorionic gonadotropin for injection, USP)

INDICATION FOR USE

  • NOVAREL is indicated for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pre-treated with human menotropins. 

IMPORTANT SAFETY INFORMATION

  • NOVAREL should not be used in patients with prior allergic reaction to HCG. HCG may cause fetal harm when administered to a pregnant woman. 
  • NOVAREL should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions, and adverse reactions described in the package insert for menotropins. The principal serious adverse reactions during this use are: (1) Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion; (2) Enlargement of preexisting ovarian cysts or rupture of ovarian cysts with resultant hemoperitoneum; (3) Multiple births, and (4) Arterial thromboembolism.
  • Anaphylaxis has been reported with urinary-derived HCG products.
  • Since androgens may cause fluid retention, HCG should be used with caution in patients with cardiac or renal disease, epilepsy, migraine, or asthma.
  • HCG can cross react in the radioimmunoassay of gonadotropins, especially luteinizing hormone. Each individual laboratory should establish the degree of cross reactivity with their gonadotropin assay. Physicians should make the laboratory aware of patients on HCG if gonadotropin levels are requested.
  • Defects of forelimbs and of the central nervous system, as well as alterations in sex ratio, have been reported in mice on combined gonadotropin and HCG regimens. The dose of gonadotropin used was intended to induce superovulation. No mutagenic effect has been clearly established in humans.
  • It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when HCG is administered to a nursing woman.
  • Adverse reactions include headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia, pain at the site of injection. Hypersensitivity reactions both localized and systemic in nature, including erythema, urticaria, rash, angioedema, dyspnea and shortness of breath, have been reported. The relationship of these allergic-like events to the polypeptide hormone or the diluent containing benzyl alcohol is not clear.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

Administering ENDOMETRIN

Download Guide

ENDOMETRIN® (progesterone) Vaginal Insert

INDICATION FOR USE

  • ENDOMETRIN® (progesterone) Vaginal Insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women. 

IMPORTANT SAFETY INFORMATION

  • ENDOMETRIN should not be used in individuals with any of the following conditions: previous allergic reactions to progesterone or any of the ingredients of ENDOMETRIN, undiagnosed vaginal bleeding, known missed abortion or ectopic pregnancy, liver disease, known or suspected breast cancer, active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events. 
  • The physician should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. ENDOMETRIN should be discontinued if any of these are suspected.
  • Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.
  • ENDOMETRIN should not be recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert.
  • The most common adverse reactions reported (greater than 5%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1.800.FDA.1088.

Please see full Prescribing Information.

Financial assistance

Cost can be an obstacle for patients seeking the treatment they need. We are committed to helping patients understand and gain access to financial assistance options that can help them.‡

‡Certain restrictions may apply. Federal healthcare program beneficiaries, including but not limited to state Medicaid and state Medicaid managed care recipients, are ineligible for the program.

Heart Tomorrow

Electing to freeze eggs

HeartTomorrow provides a discounted price for a select Ferring product for eligible cash-paying patients who are undergoing controlled ovarian stimulation (COS) for planned oocyte cryopreservation. Terms and conditions apply.

Download Brochure
Heart for Heroes

Veterans & spouses seeking IVF treatment

The Heart for Heroes program is for medically separated from active-duty Department of Defense category 2 or 3 veterans§ with a service-related injury resulting in infertility and requiring assisted reproduction, or patients and/or spouses with no insurance coverage for IVF medications. Terms and conditions apply.

Qualifying patients must be residents of the 50 United States or the District of Columbia. To learn more and for full program terms and conditions, please call 1-800-515-DRUG (3784).

§Category 2 veterans include those with a serious injury or illness, who are unlikely to return to duty within a time specified by their Military Department, and who may be medically separated from the military. Category 3 veterans include those who have a severe or catastrophic injury or illness, who are highly unlikely to return to duty, and who most likely will be medically separated from the military.

Heart Beat

Fertility preservation prior to cancer treatment

Heart Beat provides select fertility medications at no cost for eligible patients. Qualifying patients must be female, be a US citizen or permanent resident, have received a diagnosis of cancer, and have received no chemotherapy within the previous 12 months. Oncologists and reproductive endocrinologists are required to determine that fertility preservation treatment is medically appropriate. Terms and conditions apply.

To request additional information, and for full program terms and conditions, call 1-888-347-3415. For residents of Arkansas, Massachusetts, or New Jersey, please call 1-877-252-0553.

HeartFelt

Cycles canceled due to COVID-19 or a natural disaster

HeartFelt can replace medications for eligible cash-paying patients, or up to $250 towards co-pay costs for eligible commercially insured patients whose controlled ovarian stimulation (COS) cycles were canceled due to COVID or a natural disaster resulting in a federal or state emergency. Terms and conditions apply.

Download Brochure

Find a pharmacy in network

Locate pharmacies that are in network to fill patient prescriptions. This is not a complete list of pharmacies that can provide Ferring fertility products. It is limited to pharmacies within the Ferring network. Ferring fertility products may be available at other pharmacies.